JP2004508339A - 微生物病原体ワクチン - Google Patents
微生物病原体ワクチン Download PDFInfo
- Publication number
- JP2004508339A JP2004508339A JP2002524528A JP2002524528A JP2004508339A JP 2004508339 A JP2004508339 A JP 2004508339A JP 2002524528 A JP2002524528 A JP 2002524528A JP 2002524528 A JP2002524528 A JP 2002524528A JP 2004508339 A JP2004508339 A JP 2004508339A
- Authority
- JP
- Japan
- Prior art keywords
- vaccine
- stress
- gene
- heat shock
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 98
- 244000000010 microbial pathogen Species 0.000 title claims abstract description 40
- 108010004889 Heat-Shock Proteins Proteins 0.000 claims abstract description 45
- 102000002812 Heat-Shock Proteins Human genes 0.000 claims abstract description 41
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 35
- 238000000034 method Methods 0.000 claims abstract description 26
- 244000005700 microbiome Species 0.000 claims abstract description 20
- 239000000427 antigen Substances 0.000 claims abstract description 15
- 108091007433 antigens Proteins 0.000 claims abstract description 15
- 102000036639 antigens Human genes 0.000 claims abstract description 15
- 239000013598 vector Substances 0.000 claims abstract description 14
- 241000894006 Bacteria Species 0.000 claims abstract description 12
- 230000001939 inductive effect Effects 0.000 claims abstract description 9
- 239000012634 fragment Substances 0.000 claims abstract description 8
- 239000000203 mixture Substances 0.000 claims description 30
- 239000002671 adjuvant Substances 0.000 claims description 16
- 241001465754 Metazoa Species 0.000 claims description 14
- 101150023890 hspR gene Proteins 0.000 claims description 13
- 230000035939 shock Effects 0.000 claims description 12
- 101100071650 Streptomyces coelicolor (strain ATCC BAA-471 / A3(2) / M145) hspR gene Proteins 0.000 claims description 10
- 230000002163 immunogen Effects 0.000 claims description 10
- 244000052769 pathogen Species 0.000 claims description 10
- 241000607142 Salmonella Species 0.000 claims description 7
- 238000012239 gene modification Methods 0.000 claims description 7
- 108091006104 gene-regulatory proteins Proteins 0.000 claims description 7
- 230000005017 genetic modification Effects 0.000 claims description 7
- 235000013617 genetically modified food Nutrition 0.000 claims description 7
- 230000001717 pathogenic effect Effects 0.000 claims description 7
- 208000015181 infectious disease Diseases 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 241000194036 Lactococcus Species 0.000 claims description 5
- 230000028993 immune response Effects 0.000 claims description 5
- 241000187747 Streptomyces Species 0.000 claims description 4
- 230000002779 inactivation Effects 0.000 claims description 4
- 230000003204 osmotic effect Effects 0.000 claims description 4
- 229940021993 prophylactic vaccine Drugs 0.000 claims description 4
- 229960000814 tetanus toxoid Drugs 0.000 claims description 4
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims description 3
- 208000035473 Communicable disease Diseases 0.000 claims description 3
- YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical compound C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 claims description 3
- 241000589989 Helicobacter Species 0.000 claims description 3
- 241000186781 Listeria Species 0.000 claims description 3
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims description 3
- 241000607598 Vibrio Species 0.000 claims description 3
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 claims description 3
- 230000002238 attenuated effect Effects 0.000 claims description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 3
- 230000003308 immunostimulating effect Effects 0.000 claims description 3
- 244000045947 parasite Species 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 229940031439 squalene Drugs 0.000 claims description 3
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims description 3
- 229940031626 subunit vaccine Drugs 0.000 claims description 3
- 229940021747 therapeutic vaccine Drugs 0.000 claims description 3
- 241000233866 Fungi Species 0.000 claims description 2
- 230000002685 pulmonary effect Effects 0.000 claims description 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 claims 1
- 230000035882 stress Effects 0.000 abstract description 21
- 238000004519 manufacturing process Methods 0.000 abstract description 11
- 230000036039 immunity Effects 0.000 abstract description 8
- 230000008642 heat stress Effects 0.000 abstract description 2
- 230000008723 osmotic stress Effects 0.000 abstract description 2
- 230000002950 deficient Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 16
- 101100507457 Dictyostelium discoideum hspC gene Proteins 0.000 description 15
- 102000007079 Peptide Fragments Human genes 0.000 description 10
- 108010033276 Peptide Fragments Proteins 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 101100125027 Dictyostelium discoideum mhsp70 gene Proteins 0.000 description 6
- 101150031823 HSP70 gene Proteins 0.000 description 6
- 108700025695 Suppressor Genes Proteins 0.000 description 6
- 101150052825 dnaK gene Proteins 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 108700005075 Regulator Genes Proteins 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 101100016370 Danio rerio hsp90a.1 gene Proteins 0.000 description 4
- 101100285708 Dictyostelium discoideum hspD gene Proteins 0.000 description 4
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 4
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 4
- 101100071627 Schizosaccharomyces pombe (strain 972 / ATCC 24843) swo1 gene Proteins 0.000 description 4
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 4
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 4
- 235000011130 ammonium sulphate Nutrition 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000002103 transcriptional effect Effects 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000004077 genetic alteration Effects 0.000 description 3
- 231100000118 genetic alteration Toxicity 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000016784 immunoglobulin production Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 201000008827 tuberculosis Diseases 0.000 description 3
- 102000006303 Chaperonin 60 Human genes 0.000 description 2
- 108010058432 Chaperonin 60 Proteins 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000186366 Mycobacterium bovis Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 102000034356 gene-regulatory proteins Human genes 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000000863 peptide conjugate Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108700041152 Endoplasmic Reticulum Chaperone BiP Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 101150112743 HSPA5 gene Proteins 0.000 description 1
- 101150101832 HSPA9 gene Proteins 0.000 description 1
- 101150065069 Hsp90b1 gene Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 241000187644 Mycobacterium vaccae Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 101150115114 dnaJ gene Proteins 0.000 description 1
- 108010063187 endoplasmic reticulum glycoprotein p99 Proteins 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 229940031689 heterologous vaccine Drugs 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000002743 insertional mutagenesis Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 210000005061 intracellular organelle Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6043—Heat shock proteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0021757.0A GB0021757D0 (en) | 2000-09-04 | 2000-09-04 | Vaccine against microbial pathogens |
| PCT/GB2001/003964 WO2002020045A2 (en) | 2000-09-04 | 2001-09-04 | Vaccine against microbial pathogens |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004508339A true JP2004508339A (ja) | 2004-03-18 |
| JP2004508339A5 JP2004508339A5 (enExample) | 2008-10-16 |
Family
ID=9898866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002524528A Pending JP2004508339A (ja) | 2000-09-04 | 2001-09-04 | 微生物病原体ワクチン |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20050232946A1 (enExample) |
| EP (1) | EP1315518B1 (enExample) |
| JP (1) | JP2004508339A (enExample) |
| CN (1) | CN1452495A (enExample) |
| AT (1) | ATE450270T1 (enExample) |
| AU (1) | AU2001284261A1 (enExample) |
| CA (1) | CA2421229A1 (enExample) |
| DE (1) | DE60140681D1 (enExample) |
| DK (1) | DK1315518T3 (enExample) |
| ES (1) | ES2337653T3 (enExample) |
| GB (1) | GB0021757D0 (enExample) |
| IL (1) | IL154727A0 (enExample) |
| PT (1) | PT1315518E (enExample) |
| WO (1) | WO2002020045A2 (enExample) |
| ZA (1) | ZA200301759B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010501595A (ja) * | 2006-09-01 | 2010-01-21 | シーエスエル、リミテッド | 免疫応答を誘発または誘導する方法 |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7928264B2 (en) * | 2004-09-21 | 2011-04-19 | Astellas Pharma Inc. | Aminoalcohol derivatives |
| WO2009021291A1 (en) * | 2007-08-16 | 2009-02-19 | The University Of Sydney | Mycobacterium vaccine formulation |
| US8999353B2 (en) | 2007-10-12 | 2015-04-07 | Csl Limited | Method of eliciting an immune response against pandemic influenza virus |
| GB0910591D0 (en) | 2009-06-19 | 2009-07-29 | Immunobiology Ltd | Method for the purification of protein complexes |
| GB0916557D0 (en) | 2009-09-21 | 2009-10-28 | Health Prot Agency | Commensal neisserial stress protein complexes |
| GB201104897D0 (en) | 2011-03-23 | 2011-05-04 | Immunobiology Ltd | Method for the production of protein complexes and vaccine compositions comprising the same |
| BR112013026929A2 (pt) * | 2011-04-20 | 2016-12-27 | Mico Bio Inc | composição e método para intensificação de uma resposta imune |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03204820A (ja) * | 1989-10-12 | 1991-09-06 | Nippon Saibai Suisan Kk | エビ類の細菌性疾病予防ワクチン及びその製造法 |
| JPH10291938A (ja) * | 1986-08-18 | 1998-11-04 | British Technol Group Ltd | 生ワクチン |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5776724A (en) * | 1988-10-24 | 1998-07-07 | Yale University | Chaperonin-mediated protein folding |
| JPH08509873A (ja) * | 1993-05-19 | 1996-10-22 | アンスティテュ・パストゥール | ヘリコバクター感染に対する免疫組成物、該組成物に用いられるポリペプチドおよび該ポリペプチドをコードする核酸配列 |
| US6258359B1 (en) * | 1993-05-19 | 2001-07-10 | Institut Pasteur | Immunogenic compositions against helicobacter infection, polypeptides for use in the compositions, and nucleic acid sequences encoding said polypeptides |
| JPH0748398A (ja) * | 1993-08-03 | 1995-02-21 | Nippon Oil Co Ltd | 変性蛋白質の再生方法及び変性蛋白質再生剤 |
| US6872542B1 (en) * | 1993-11-18 | 2005-03-29 | Siga Pharmaceuticals, Inc. | Treatment or prophylaxis of diseases caused by pilus-forming bacteria |
| US6420127B1 (en) * | 1994-11-18 | 2002-07-16 | Washington University | Compounds and pharmaceutical compositions for the treatment and prophylaxis of bacterial infections |
| US5961979A (en) * | 1994-03-16 | 1999-10-05 | Mount Sinai School Of Medicine Of The City University Of New York | Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens |
| WO1996040928A1 (en) * | 1995-06-07 | 1996-12-19 | Biochem Vaccines Inc. | Streptococcal heat shock proteins members of the hsp70 family |
| US5935576A (en) * | 1995-09-13 | 1999-08-10 | Fordham University | Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens |
| JP2000502054A (ja) * | 1995-11-30 | 2000-02-22 | アグリカルチャー ビクトリア サービシーズ ピーティーワイ．エルティーディー． | 治療用および診断用の組成物 |
| US6066716A (en) * | 1996-09-20 | 2000-05-23 | University Of New Mexico | Purified heat shock protein complexes |
| US5747332A (en) * | 1996-09-20 | 1998-05-05 | University Of New Mexico | Methods for purifying and synthesizing heat shock protein complexes |
| US6331388B1 (en) * | 1997-10-17 | 2001-12-18 | Wisconsin Alumni Research Foundation | Immune response enhancer |
| US5948646A (en) * | 1997-12-11 | 1999-09-07 | Fordham University | Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes |
| US6500434B1 (en) * | 1998-04-23 | 2002-12-31 | Medimmune, Inc. | Chaperone and adhesin proteins; vaccines, diagnostics and method for treating infections |
| US6248329B1 (en) * | 1998-06-01 | 2001-06-19 | Ramaswamy Chandrashekar | Parasitic helminth cuticlin nucleic acid molecules and uses thereof |
| AU770498B2 (en) * | 1998-06-19 | 2004-02-26 | Merieux Oravax | LT and CT in parenteral immunization methods against helicobacter infection |
| GB9818133D0 (en) * | 1998-08-19 | 1998-10-14 | Quadrant Holdings Cambridge | Vaccine |
| JP2002537351A (ja) * | 1999-02-22 | 2002-11-05 | ユニバーシティ・オブ・ブリティッシュ・コロンビア | コーロバクターリポ多糖免疫アジュバント |
| US7041465B1 (en) * | 1999-08-11 | 2006-05-09 | Washington University | Anti-bacterial compounds directed against pilus biogenesis, adhesion and activity; co-crystals of pilus subunits and methods of use thereof |
| GB9919734D0 (en) * | 1999-08-19 | 1999-10-20 | Colaco Camilo | Vaccines from infectious agents |
| US6677139B1 (en) * | 1999-12-23 | 2004-01-13 | Genecor International, Inc. | Methods for production of proteins in host cells |
| GB0004547D0 (en) * | 2000-02-23 | 2000-04-19 | Immunobiology Ltd | Screening method for novel vaccine candidates and compositions obtained thereby |
| AU2001257087A1 (en) * | 2000-04-17 | 2001-10-30 | Mojave Therapeutics Inc. | Heat shock protein-based antiviral vaccines |
| CN1107681C (zh) * | 2000-08-11 | 2003-05-07 | 中国科学院微生物研究所 | 乙肝病毒抗原多肽与热休克蛋白的复合物及其应用 |
| US6932985B2 (en) * | 2000-10-10 | 2005-08-23 | Auburn University | Azide method and composition for controlling deleterious organisms |
| WO2002059156A2 (en) * | 2000-12-22 | 2002-08-01 | Medimmune, Inc. | Therapeutic compounds structurally-linked to bacterial polypeptides |
| WO2003068941A2 (en) * | 2002-02-13 | 2003-08-21 | Duke University | Modulation of immune response by non-peptide binding stress response polypeptides |
| WO2003074003A2 (en) * | 2002-03-01 | 2003-09-12 | Applied Immune Technologies | Immunogens for treatment of neoplastic and infectious disease |
| CA2483925A1 (en) * | 2002-05-02 | 2004-04-29 | University Of Connecticut Health Center | Using heat shock proteins and alpha-2-macroglobulins to increase immune response to vaccines comprising heat shock protein-peptide complexes or alpha-2-macroglobulin-peptide complexes |
-
2000
- 2000-09-04 GB GBGB0021757.0A patent/GB0021757D0/en not_active Ceased
-
2001
- 2001-09-04 WO PCT/GB2001/003964 patent/WO2002020045A2/en not_active Ceased
- 2001-09-04 US US10/363,454 patent/US20050232946A1/en not_active Abandoned
- 2001-09-04 ES ES01963230T patent/ES2337653T3/es not_active Expired - Lifetime
- 2001-09-04 PT PT01963230T patent/PT1315518E/pt unknown
- 2001-09-04 EP EP01963230A patent/EP1315518B1/en not_active Expired - Lifetime
- 2001-09-04 CA CA002421229A patent/CA2421229A1/en not_active Abandoned
- 2001-09-04 AT AT01963230T patent/ATE450270T1/de active
- 2001-09-04 DK DK01963230.6T patent/DK1315518T3/da active
- 2001-09-04 CN CN01815133A patent/CN1452495A/zh active Pending
- 2001-09-04 JP JP2002524528A patent/JP2004508339A/ja active Pending
- 2001-09-04 AU AU2001284261A patent/AU2001284261A1/en not_active Abandoned
- 2001-09-04 DE DE60140681T patent/DE60140681D1/de not_active Expired - Lifetime
- 2001-09-04 IL IL15472701A patent/IL154727A0/xx unknown
-
2003
- 2003-03-03 ZA ZA200301759A patent/ZA200301759B/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10291938A (ja) * | 1986-08-18 | 1998-11-04 | British Technol Group Ltd | 生ワクチン |
| JPH03204820A (ja) * | 1989-10-12 | 1991-09-06 | Nippon Saibai Suisan Kk | エビ類の細菌性疾病予防ワクチン及びその製造法 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010501595A (ja) * | 2006-09-01 | 2010-01-21 | シーエスエル、リミテッド | 免疫応答を誘発または誘導する方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| GB0021757D0 (en) | 2000-10-18 |
| DK1315518T3 (da) | 2010-04-19 |
| AU2001284261A1 (en) | 2002-03-22 |
| IL154727A0 (en) | 2003-10-31 |
| ES2337653T3 (es) | 2010-04-28 |
| ZA200301759B (en) | 2004-06-22 |
| CN1452495A (zh) | 2003-10-29 |
| EP1315518A2 (en) | 2003-06-04 |
| WO2002020045A3 (en) | 2002-10-31 |
| WO2002020045A2 (en) | 2002-03-14 |
| DE60140681D1 (de) | 2010-01-14 |
| US20050232946A1 (en) | 2005-10-20 |
| EP1315518B1 (en) | 2009-12-02 |
| PT1315518E (pt) | 2010-03-05 |
| CA2421229A1 (en) | 2002-03-14 |
| ATE450270T1 (de) | 2009-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20060140975A1 (en) | Regulated bacterial lysis for gene vaccine vector delivery and antigen release | |
| Singh | Salmonella vaccines for animals and birds and their future perspective | |
| Hajam et al. | Incorporation of membrane-anchored flagellin into Salmonella Gallinarum bacterial ghosts induces early immune responses and protection against fowl typhoid in young layer chickens | |
| JP2005538923A (ja) | ミコバクテリアワクチン | |
| EP1315518B1 (en) | Vaccine against microbial pathogens | |
| US20050175635A1 (en) | Method and composition | |
| EP1204422B1 (en) | Stress-proteins from extra-cellular pathogens as vaccines against infectious agents | |
| JP2004507453A (ja) | 組換え細胞内病原体ワクチンおよび使用のための方法 | |
| JP2004508339A5 (enExample) | ||
| Dietrich et al. | Haemolysin A and listeriolysin–two vaccine delivery tools for the induction of cell-mediated immunity | |
| AU2005204321B2 (en) | Vaccines from Infectious Agents | |
| CA2382331C (en) | Vaccine against intra-cellular pathogens | |
| Hormaeche | Immunity to Salmonella | |
| Harrison et al. | Use of the TraT lipoprotein to stimulate immune responses to foreign antigens in live salmonella vaccine strains | |
| Tacket et al. | Clinical acceptability and immunogenicity of CVD 908 Salmonella typhi vaccine carrier strain | |
| Mukkur | Prophylactic use of live metabolite-deficient salmonella species as vaccines in ruminant animals | |
| Kumar | Vaccines Against Leishmaniasis | |
| Stittelaar | Attenuated Organisms as Vaccines | |
| Kennedy | The view on vaccination. | |
| AU2005204218A1 (en) | Vaccine Against Intra-Cellular Pathogens |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080827 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080827 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110614 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20111220 |